ImmunityBio (IBRX) versus The Competition Critical Analysis

ImmunityBio (NASDAQ:IBRX) is one of 282 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare ImmunityBio to related businesses based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, risk, earnings and dividends.

Profitability

This table compares ImmunityBio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-93,761.41%	N/A	-114.56%
ImmunityBio Competitors	-4,428.78%	-224.08%	-44.94%

Risk and Volatility

ImmunityBio has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, ImmunityBio’s rivals have a beta of 0.99, suggesting that their average stock price is 1% less volatile than the S&P 500.

Institutional and Insider Ownership

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 83.4% of ImmunityBio shares are owned by insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares ImmunityBio and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ImmunityBio	$620,000.00	-$583.20 million	-4.23
ImmunityBio Competitors	$562.17 million	-$34.62 million	6.70

ImmunityBio’s rivals have higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and target prices for ImmunityBio and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0	1	0	0	2.00
ImmunityBio Competitors	1422	4535	11770	202	2.60

ImmunityBio presently has a consensus price target of $5.00, suggesting a potential upside of 1.83%. As a group, “Biological products, except diagnostic” companies have a potential upside of 127.56%. Given ImmunityBio’s rivals stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio has less favorable growth aspects than its rivals.

Summary

ImmunityBio rivals beat ImmunityBio on 10 of the 13 factors compared.

About ImmunityBio

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.